Table 1 Effects of bisphosphonates in animal models of breast cancer
Animal model | Bisphosphonate | Type of protocol (preventative/therapeutic) | Effects on skeletal metastases | Effects on extraskeletal metastases | Reference |
|---|---|---|---|---|---|
MDA-MB-231 breast cancer (intracardiac) | Risedronate | Preventative | ↓ new skeletal metastases | No effect | Sasaki et al. (1995) [21] |
|  |  | Therapeutic | ↓ progression of existing skeletal metastases | No effect |  |
MDA-MB-231 breast cancer (intracardiac) | YH529 | Preventative | ↓ skeletal metastases | ↑ at low doses; ↓ at higher dose | Sasaki et al. (1998) [22] |
| Â | Â | Therapeutic | No change | No change | Â |
MDA-MB-231 breast cancer (intracardiac) | Ibandronate | Preventative | ↓ skeletal metastases | ↑ adrenal metastases | Yoneda et al. (2000) [23] |
|  |  | Therapeutic | ↓ progression of established skeletal metastases | No effect |  |
4T1, mouse mammary tumor cell line (orthotopic) | Zoledronate | Preventative | ↓ skeletal metastases | No effect on primary tumor or visceral metastases | Mundy et al. (2001) [26] |
|  |  | Therapeutic | ↓ progression of established skeletal metastases | No effect |  |
ENU-1564 mammary adenocarcinoma cell line (intracardiac, rats) | Risedronate | Therapeutic | ↓ skeletal metastases | No effect | Hall and Stoico (1994) [27] |
Walker carcinosarcoma 256B cells (intra-aortic) | Clodronate | Preventative | ↓ osteolysis; no change in number of skeletal metastases | No effect | Krempien and Manegold (1993) [29] |
Walker carcinosarcoma 256B cells (intra-aortic) | Pamidronate | Preventative | ↓ skeletal metastases | No effect | Krempien e tal. (1998) [30] |
MCF-7* breast cancer (intracardiac) | Ibandronate | Preventative | ↓ skeletal metastases (osteoblastic) | No effect | Yoneda e tal. (2000) [23] |
| Â | Â | Therapeutic | No effect | No effect | Â |